BiotechTube

AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epithelial Ovarian Cancer

Conditions

Epithelial Ovarian Cancer

Trial Timeline

Dec 29, 2025 → May 27, 2030

NCT ID
NCT07218809

About AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan

AZD5335 + Mirvetuximab Soravtansine (MIRV) + Paclitaxel + Pegylated liposomal Doxorubicin (PLD) + Topotecan is a phase 3 stage product being developed by AstraZeneca for Epithelial Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218809. Target conditions include Epithelial Ovarian Cancer.

What happened to similar drugs?

4 of 12 similar drugs in Epithelial Ovarian Cancer were approved

Approved (4) Terminated (1) Active (8)
🔄Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
🔄Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
✅Olaparib + BevacizumabAstraZenecaApproved
🔄Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
🔄Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
🔄V501MerckPhase 3
✅intravitreal injection with ranibizumabNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07218809Phase 3Recruiting

Competing Products

20 competing products in Epithelial Ovarian Cancer

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
LY2228820 + Carboplatin + Placebo + GemcitabineEli LillyPhase 1/2
32
gemcitabine + carboplatin + paclitaxelEli LillyPhase 2
35
PemetrexedEli LillyPhase 2
35
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Mirvetuximab Soravtansine + Paclitaxel + Topotecan + Pegylated liposomal doxorubicinAbbViePhase 3
40
Carboplatin + Mirvetuximab Soravtansine + BevacizumabAbbViePhase 2
42
Mirvetuximab SoravtansineAbbViePhase 2
42
AvelumabAstraZenecaPhase 2
27
Active Comparator: Olaparib tablets + PlaceboAstraZenecaPhase 3
40
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weeklyAstraZenecaPhase 2
31
Olaparib + BevacizumabAstraZenecaApproved
47
Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-concomitant) + Comparator: Adacel™MerckPhase 3
40
PembrolizumabMerckPhase 2
42
MK-1775 and carboplatinMerckPhase 2
35
GardasilMerckPhase 1
29
NG-350A plus PembrolizumabMerckPhase 1
29
Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)MerckPhase 3
40
V501MerckPhase 3
40
9-valent HPV vaccinationMerckPhase 2
42